On Biostatistics and Clinical Trials

CQ's web blog on the issues in biostatistics and clinical trials.

Wednesday, November 07, 2018

FDA launches new digital tool to help capture real world data from patients to help inform regulatory decision-making

›
FDA In Brief: FDA launches new digital tool to help capture real world data from patients to help inform regulatory decision-making FDA’s My...
Thursday, November 01, 2018

Fitting Compartment Models Using PROC NLMIXED

›
There is a new article on SAS's website " Fitting Compartment Models Using PROC NLMIXED ". It is nice to know that SAS Proc NL...
Monday, October 22, 2018

Potential Unblinding due to Imbalance in Adverse Event Profiles

›
In a previous post “ Is blinded study really blinded? - assessment of blinding/unblinding in clinical trials ”, we discussed the potential...
1 comment:
Sunday, October 07, 2018

Latin Squares for Constructing "Williams Designs" - Balanced for First-order Carry-over (Residual) Effects

›
Courtesy from the website  http://statpages.info/latinsq.html , the list below contains the Williams design with 2 to 26 treatment groups. I...
3 comments:
Monday, September 10, 2018

Randomized Withdrawal Design - Examples for Defining the Criteria for Run-in and Randomized Withdrawal Periods

›
In a previous post, we discussed the " Randomized Withdrawal Design and Randomized Discontinuation Trial ". The randomized withdra...
Thursday, September 06, 2018

FDA Guidance: Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics

›
Two years ago, I had a post discussing " Dose Cohort Expansion Study - A Never Ending Phase I Study Design ". Last month, FDA offi...
Saturday, August 11, 2018

Splitting p-value and estimate of the treatment difference

›
When we perform the statistical test to compare the difference between two treatment groups, we usually construct a test statistic, calcula...
1 comment:
Sunday, July 01, 2018

Geriatric Investigational Plan - Clinical Trials for Elderly

›
Every clinical trial should have a protocol and the protocol needs to include the inclusion/exclusio criteria to define the study population...
‹
›
Home
View web version

About Me

My photo
Web blog from Dr. Deng
Chapel Hill, NC, United States
邓春勤 A Medical Doctor turned into Biostatistician in Clinical Trial and Drug Development Industry
View my complete profile
Powered by Blogger.